ProCE Banner Activity

Clinical Impact of New Data on Crohn’s Disease and Ulcerative Colitis

Slideset Download
Conference Coverage

Download these slides for expert insights on key trials presented at ECCO 2022 and the impact the data will have in the management of patients with Crohn disease and ulcerative colitis.

Released: May 06, 2022

Expiration: May 05, 2023

No longer available for credit.

Share

Faculty

Uma Mahadevan

Uma Mahadevan, MD

Professor of Medicine, Division of Gastroenterology
Director, Center for Colitis and Crohn’s Disease
University of California San Francisco Medical School
San Francisco, California

Bruce E. Sands

Bruce E. Sands, MD, MS

Dr. Burrill B. Crohn Professor of Medicine
Chief of the Dr. Henry D. Janowitz Division of Gastroenterology

Mount Sinai Hospital
Chief, Division of Gastroenterology
Mount Sinai Health System
Director, Digestive Disease Institute
Icahn School of Medicine at Mount Sinai
New York, New York

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from

Bristol Myers Squibb

Faculty Disclosure

Primary Author

Uma Mahadevan, MD

Professor of Medicine, Division of Gastroenterology
Director, Center for Colitis and Crohn’s Disease
University of California San Francisco Medical School
San Francisco, California

Uma Mahadevan, MD, has disclosed that she has received consulting fees from AbbVie, Arena, Bristol-Myers Squibb, Boehringer Ingelheim, Calibr, Gilead, Janssen, Pfizer, Prometheus Biosciences, Protagonist, Surrozen, and Takeda.

Bruce E. Sands, MD, MS

Dr. Burrill B. Crohn Professor of Medicine
Chief of the Dr. Henry D. Janowitz Division of Gastroenterology

Mount Sinai Hospital
Chief, Division of Gastroenterology
Mount Sinai Health System
Director, Digestive Disease Institute
Icahn School of Medicine at Mount Sinai
New York, New York

Bruce E. Sands, MD, MS, has disclosed that he has received funds for research support from Janssen and Theravance Biopharma R&D; has received consulting fees from Abivax, AbbVie, Alimentiv, Amgen, Arena, Artugen, AstraZeneca, Bacainn, Boehringer Ingelheim, Boston Pharmaceuticals, Bristol-Myers Squibb, Calibr, Celltrion, ClostraBio, Enthera, Evommune, Ferring, Galapagos, Gilead, GlaxoSmithKline, GossamerBio, Immunic, Index, Innovation, Ironwood, Janssen, Kaleido, Kallyope, Lilly, MiroBio, MRM Health, Morphic Therapeutic, Pfizer, Progenity, Prometheus Biosciences, Protagonist Therapeutics, Q32 Bio, Sun Pharma, Surrozen, Takeda, Target RWE, Teva Branded Pharmaceutical Products R&D, Thelium, Theravance Biopharma R&D, TLL Pharma, USWM Enterprises, Ventyx Biosciences, Viela Bio; and has ownership interest in Ventyx.